Novavax has appointed Margaret McGlynn, to its board as an independent director. She has extensive pharmaceutical industry, vaccine and non-profit experience to her role on the Novavax Board of Directors.
“Margie’s deep experience in vaccine commercialisation and understanding of global public health will be invaluable as we move closer to collecting Phase III clinical data and submitting NVX-CoV2373, our COVID-19 vaccine candidate, for regulatory authorisation and approval,” said Stanley Erck, Novavax President and Chief Executive Officer.
McGlynn is currently President and Board Chair for HCU Network America, an advocacy organisation she founded in 2016 that is dedicated to supporting the needs of those impacted by the rare genetic condition homocystinuria (HCU) and related disorders.
Prior to founding HCU Network America, she served as President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), where she led extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine. She previously spent more than two decades at Merck, where she held roles including President of Merck Vaccines and Infectious Diseases.
“This is a very exciting time to be joining the Novavax Board, and I look forward to working with my fellow directors to support Novavax’ critical priority to advance and deploy NVX-CoV2373 globally to help end this devastating pandemic, as well as progress the broader vaccine portfolio,” said McGlynn.
